Last edition
News about "Sun Pharmaceutical Industries "
US FDA Imports Alert Hits Sun Pharma's Halol Manufacturing Plant After OAI Classification
Sun Pharmaceutical Industries has confirmed that its Halol manufacturing facility in Gujarat, India, has been classified as “Official Action Indicated” (OAI) by the US Food and Drug Administration following a compliance inspection conducted in June 2025.
Sun Pharmaceutical Industries | 11/09/2025 | By Darshana
Sun Pharma Halol Facility Classified OAI by US FDA, Shipments Restricted
The US Food and Drug Administration (FDA) has classified Sun Pharma's Halol facility as “Official Action Indicated” (OAI) following an inspection conducted between June 2 and June 13, 2025.
Sun Pharmaceutical Industries | 10/09/2025 | By Dineshwori | 110
Sun Pharmaceutical Industries has reported positive top-line results from two Phase 3 trials (INSPIRE-1 and INSPIRE-2), demonstrating that ILUMYA (tildrakizumab 100 mg) significantly improved symptoms of active psoriatic arthritis over 24 weeks compared to placebo.
Sun Pharmaceutical Industries | 21/07/2025 | By Mrinmoy Dey | 147
Sun Pharma Presents LEQSELVITM Data at 2024 Fall Clinical Dermatology Conference
LEQSELVI data presented at Fall Clinical includes pooled long-term results from open-label extension (OLE) studies showing ongoing and clinically meaningful improvements in scalp hair regrowth in adults with AA taking LEQSELVI for up to 68 weeks.
Sun Pharmaceutical Industries | 28/10/2024 | By Aishwarya | 283
Sun Pharma Launches a Tedizolid Phosphate Tablets in India
STARIZO (Tedizolid Phosphate) is a novel, oxazolidinone-class antibacterial, used to treat Acute Bacterial Skin and Skin Structure Infection (ABSSSI).
Sun Pharmaceutical Industries | 26/08/2024 | By Aishwarya | 447
Sun Pharma to Invest Upto USD 15 Million for 5 Percent Stake in Pharmazz
Sun Pharma described the investment as strategic, noting it will gain exclusive rights to market and distribute Pharmazz’s drug, Sovateltide, in certain emerging markets.
Sun Pharmaceutical Industries | 17/08/2024 | By Aishwarya | 455
Sun Pharma Gets US FDA Approval for LEQSELVI for Treatment of Severe Alopecia Areata
Sun Pharmaceutical Industries Ltd. has announced that the US Food and Drug Administration (FDA) has approved LEQSELVI (deuruxolitinib) 8 mg tablets for the treatment of adults with severe alopecia areata.
Sun Pharmaceutical Industries | 26/07/2024 | By Aishwarya | 854
Sun Pharmaceutical Industries and Moebius Medical have presented data demonstrating the durability of pain relief achieved in symptomatic knee OA patients through 26 weeks post injection of MM-II.
Sun Pharmaceutical Industries | 15/06/2024 | By Aishwarya | 454
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy